<DOC>
	<DOCNO>NCT01457807</DOCNO>
	<brief_summary>To evaluate pharmacokinetics AZD3241 follow multiple administration 2 new , different extend release formulation tablet AZD3241 ( 300 mg ) , relation 100 mg extend release tablet use previous study potential food interaction . The safety tolerability AZD 3241 also investigate secondary objective . In addition number exploratory objective investigate blood sampling .</brief_summary>
	<brief_title>To Assess Effect Administration 2 Formulation AZD3241 Blood Concentration Healthy Volunteers</brief_title>
	<detailed_description>A Phase I , Single-centre , Double-blind , Randomised , Placebo-controlled , Parallel Group Study Assess Pharmacokinetics , Safety Tolerability Two Different Extended Release Formulations Tablets AZD3241 ( 300 mg ) Administration Multiple Doses Healthy Male Female Volunteers</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Provision sign date , write informed consent prior study specific procedure Healthy male female volunteer age 30 65 year , inclusive , suitable vein cannulation repeat venepuncture Female volunteer must negative pregnancy test Screening admission CPU , must lactate must non childbearing potential , confirm Screening Male volunteer must willing use barrier contraception ie , condom , first day dose administration 3 month last dose IP Volunteers must body mass index ( BMI ) 18 30 kg/m2 weigh least 50 kg 100 kg History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge Investigator history hypersensitivity drug similar chemical structure class AZD3241 Orthostatic hypotension define 25 mmHg decrease systolic and/or 15 mmHg decrease diastolic BP measure enrolment and/or randomisation History intolerance hypersensitivity mannitol Prolonged QT interval correct heart rate use Fridericia 's formula ( QTcF ) &gt; 450 m shorten QTcF &lt; 340 m family history long QT syndrome Abnormal vital sign , 10 minute rest supine position , define follow : Systolic BP &gt; 140 mmHg. , Diastolic BP &gt; 90 mmHg. , Heart rate &lt; 40 &gt; 85 beat per minute .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>biomarkers</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>extended release formulation</keyword>
</DOC>